#BEGIN_DRUGCARD DB02236

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
18349

# Chemical_Formula:
C7H13N2O8P

# Chemical_IUPAC_Name:
[(2S,3R,4R,5R)-5-(2-aminoacetamido)-3,4-dihydroxyoxolan-2-yl]methyl phosphate

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Glycinamide Ribonucleotide

# HET_ID:
GAR

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C7H15N2O8P/c8-1-4(10)9-7-6(12)5(11)3(17-7)2-16-18(13,14)15/h3,5-7,11-12H,1-2,8H2,(H,9,10)(H2,13,14,15)/p-2/t3-,5-,6+,7+/m0/s1

# InChI_Key:
InChIKey=OBQMLSFOUZUIOB-DOAVWBMOSA-L

# Indication:
Not Available

# KEGG_Compound_ID:
C03838

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
2236

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
284.1605

# Molecular_Weight_Mono:
284.040951914

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1EZ1

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-2.5

# Predicted_LogS:
-0.78

# Predicted_Water_Solubility:
5.33e+01 g/l

# Primary_Accession_No:
DB02236

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
46936328

# PubChem_Substance_ID:
46504693

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT01547

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
NCC(=O)N[C@@H]1O[C@@H](COP([O-])([O-])=O)[C@H](O)[C@H]1O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:20:56 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
L20897

# Drug_Target_1_GenBank_ID_Protein:
304887

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
purT

# Drug_Target_1_Gene_Sequence:
>1179 bp
ATGACGTTATTAGGCACTGCGCTGCGTCCGGCAGCAACTCGCGTGATGTTATTAGGCTCC
GGTGAACTGGGTAAAGAAGTGGCAATCGAGTGTCAGCGTCTCGGCGTAGAGGTGATTGCC
GTCGATCGCTATGCCGACGCACCAGCCATGCATGTCGCGCATCGCTCCCATGTCATTAAT
ATGCTTGATGGTGATGCATTACGCCGTGTGGTTGAACTGGAAAAACCACATTATATCGTG
CCGGAGATCGAAGCTATTGCCACCGATATGCTGATCCAACTTGAAGAGGAAGGACTGAAT
GTTGTCCCCTGCGCTCGCGCAACGAAATTAACGATGAATCGCGAGGGTATCCGTCGCCTG
GCGGCAGAAGAGCTGCAGCTGCCCACTTCCACTTATCGTTTTGCCGATAGCGAAAGCCTT
TTCCGCGAGGCGGTTGCTGACATTGGCTATCCCTGCATTGTAAAACCGGTGATGAGCTCT
TCCGGCAAGGGGCAGACGTTTATTCGTTCTGCAGAGCAACTTGCTCAGGCATGGAAGTAC
GCTCAGCAAGGCGGTCGCGCCGGAGCGGGCCGCGTAATTGTTGAAGGCGTCGTTAAGTTT
GACTTCGAAATTACCCTGCTAACCGTCAGCGCGGTGGATGGCGTCCATTTCTGTGCACCA
GTAGGTCATCGCCAGGAAGATGGCGACTACCGTGAATCCTGGCAACCACAGCAAATGAGC
CCGCTTGCCCTTGAACGTGCGCAGGAGATTGCCCGTAAAGTGGTGCTGGCACTGGGCGGT
TATGGGTTGTTTGGTGTCGAGCTATTTGTCTGTGGTGATGAGGTGATTTTCAGTGAGGTC
TCCCCTCGTCCACATGATACCGGGATGGTGACGTTAATTTCTCAAGATCTCTCAGAGTTT
GCCCTGCATGTACGTGCCTTCCTCGGACTTCCGGTTGGCGGGATCCGTCAGTATGGTCCT
GCAGCTTCTGCCGTTATTCTGCCACAACTGACCAGTCAGAATGTCACGTTTGATAATGTG
CAGAATGCCGTAGGCGCAGATTTGCAGATTCGTTTATTTGGTAAGCCGGAAATTGATGGC
AGCCGTCGTCTGGGGGTGGCACTGGCTACTGCAGAGAGTGTTGTTGACGCCATTGAACGC
GCGAAGCACGCCGCCGGACAGGTAAAAGTACAGGGTTAA

# Drug_Target_1_General_Function:
Nucleotide transport and metabolism

# Drug_Target_1_General_References:
10913290	Thoden JB, Firestine S, Nixon A, Benkovic SJ, Holden HM: Molecular structure of Escherichia coli PurT-encoded glycinamide ribonucleotide transformylase. Biochemistry. 2000 Aug 1;39(30):8791-802.
8117714	Marolewski A, Smith JM, Benkovic SJ: Cloning and characterization of a new purine biosynthetic enzyme: a non-folate glycinamide ribonucleotide transformylase from E. coli. Biochemistry. 1994 Mar 8;33(9):2531-7.
9097040	Itoh T, Aiba H, Baba T, Hayashi K, Inada T, Isono K, Kasai H, Kimura S, Kitakawa M, Kitagawa M, Makino K, Miki T, Mizobuchi K, Mori H, Mori T, Motomura K, Nakade S, Nakamura Y, Nashimoto H, Nishio Y, Oshima T, Saito N, Sampei G, Seki Y, Horiuchi T, et al.: A 460-kb DNA sequence of the Escherichia coli K-12 genome corresponding to the 40.1-50.0 min region on the linkage map. DNA Res. 1996 Dec 31;3(6):379-92.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
2817

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
42434

# Drug_Target_1_Name:
Phosphoribosylglycinamide formyltransferase 2

# Drug_Target_1_Number_of_Residues:
392

# Drug_Target_1_PDB_ID:
1EZ1

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF02222	ATP-grasp

# Drug_Target_1_Protein_Sequence:
>Phosphoribosylglycinamide formyltransferase 2
MTLLGTALRPAATRVMLLGSGELGKEVAIECQRLGVEVIAVDRYADAPAMHVAHRSHVIN
MLDGDALRRVVELEKPHYIVPEIEAIATDMLIQLEEEGLNVVPCARATKLTMNREGIRRL
AAEELQLPTSTYRFADSESLFREAVADIGYPCIVKPVMSSSGKGQTFIRSAEQLAQAWKY
AQQGGRAGAGRVIVEGVVKFDFEITLLTVSAVDGVHFCAPVGHRQEDGDYRESWQPQQMS
PLALERAQEIARKVVLALGGYGLFGVELFVCGDEVIFSEVSPRPHDTGMVTLISQDLSEF
ALHVRAFLGLPVGGIRQYGPAASAVILPQLTSQNVTFDNVQNAVGADLQIRLFGKPEIDG
SRRLGVALATAESVVDAIERAKHAAGQVKVQG

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Catalyzes two reactions:the first one is the production of beta-formyl glycinamide ribonucleotide (GAR) from formate, ATP and beta GAR; the second, a side reaction, is the production of acetyl phosphate and ADP from acetate and ATP

# Drug_Target_1_SwissProt_ID:
P33221

# Drug_Target_1_SwissProt_Name:
PURT_ECOLI

# Drug_Target_1_Synonyms:
5'-phosphoribosylglycinamide transformylase 2
EC 2.1.2.-
Formate-dependent GAR transformylase
GAR transformylase 2
GART 2

# Drug_Target_1_Theoretical_pI:
5.46

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Not Available

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
M13747

# Drug_Target_2_GenBank_ID_Protein:
147425

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
purN

# Drug_Target_2_Gene_Sequence:
>639 bp
ATGAATATTGTGGTGCTTATTTCCGGCAACGGAAGTAATTTACAGGCAATTATTGACGCC
TGTAAAACCAACAAAATTAAAGGCACCGTACGGGCAGTTTTCAGCAATAAGGCCGACGCG
TTCGGCCTTGAACGCGCCCGCCAGGCGGGTATTGCAACGCATACGCTCATCGCCAGCGCG
TTTGACAGTCGTGAAGCCTATGACCGGGAGTTGATTCATGAAATCGACATGTACGCACCC
GATGTGGTCGTGCTGGCTGGTTTTATGCGCATTCTCAGCCCGGCGTTTGTCTCCCACTAT
GCCGGGCGTTTGCTGAACATTCACCCTTCTCTGCTGCCGAAATATCCCGGATTACACACC
CATCGTCAGGCGCTGGAAAATGGCGATGAAGAGCACGGTACATCGGTGCATTTCGTCACC
GATGAACTGGACGGTGGCCCGGTTATTTTACAGGCGAAAGTCCCGGTATTTGCTGGTGAT
TCGGAAGATGACATCACCGCCCGCGTGCAAACCCAGGAACACGCCATTTATCCACTGGTG
ATTAGCTGGTTTGCCGATGGTCGTCTGAAAATGCACGAAAACGCCGCGTGGCTGGATGGT
CAACGTCTGCCGCCGCAGGGCTACGCTGCCGACGAGTAA

# Drug_Target_2_General_Function:
Nucleotide transport and metabolism

# Drug_Target_2_General_References:
10606510	Greasley SE, Yamashita MM, Cai H, Benkovic SJ, Boger DL, Wilson IA: New insights into inhibitor design from the crystal structure and NMR studies of Escherichia coli GAR transformylase in complex with beta-GAR and 10-formyl-5,8,10-trideazafolic acid. Biochemistry. 1999 Dec 21;38(51):16783-93.
10954745	Pupo GM, Lan R, Reeves PR: Multiple independent origins of Shigella clones of Escherichia coli and convergent evolution of many of their characteristics. Proc Natl Acad Sci U S A. 2000 Sep 12;97(19):10567-72.
1522592	Chen P, Schulze-Gahmen U, Stura EA, Inglese J, Johnson DL, Marolewski A, Benkovic SJ, Wilson IA: Crystal structure of glycinamide ribonucleotide transformylase from Escherichia coli at 3.0 A resolution. A target enzyme for chemotherapy. J Mol Biol. 1992 Sep 5;227(1):283-92.
1631098	Almassy RJ, Janson CA, Kan CC, Hostomska Z: Structures of apo and complexed Escherichia coli glycinamide ribonucleotide transformylase. Proc Natl Acad Sci U S A. 1992 Jul 1;89(13):6114-8.
2204419	Inglese J, Smith JM, Benkovic SJ: Active-site mapping and site-specific mutagenesis of glycinamide ribonucleotide transformylase from Escherichia coli. Biochemistry. 1990 Jul 17;29(28):6678-87.
3301838	Smith JM, Daum HA 3rd: Identification and nucleotide sequence of a gene encoding 5'-phosphoribosylglycinamide transformylase in Escherichia coli K12. J Biol Chem. 1987 Aug 5;262(22):10565-9.
9205837	Yamamoto Y, Aiba H, Baba T, Hayashi K, Inada T, Isono K, Itoh T, Kimura S, Kitagawa M, Makino K, Miki T, Mitsuhashi N, Mizobuchi K, Mori H, Nakade S, Nakamura Y, Nashimoto H, Oshima T, Oyama S, Saito N, Sampei G, Satoh Y, Sivasundaram S, Tagami H, Horiuchi T, et al.: Construction of a contiguous 874-kb sequence of the Escherichia coli -K12 genome corresponding to 50.0-68.8 min on the linkage map and analysis of its sequence features. DNA Res. 1997 Apr 28;4(2):91-113.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.
9698564	Su Y, Yamashita MM, Greasley SE, Mullen CA, Shim JH, Jennings PA, Benkovic SJ, Wilson IA: A pH-dependent stabilization of an active site loop observed from low and high pH crystal structures of mutant monomeric glycinamide ribonucleotide transformylase at 1.8 to 1.9 A. J Mol Biol. 1998 Aug 21;281(3):485-99.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
2689

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
23239

# Drug_Target_2_Name:
Phosphoribosylglycinamide formyltransferase

# Drug_Target_2_Number_of_Residues:
212

# Drug_Target_2_PDB_ID:
1JKX

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00551	Formyl_trans_N

# Drug_Target_2_Protein_Sequence:
>Phosphoribosylglycinamide formyltransferase
MNIVVLISGNGSNLQAIIDACKTNKIKGTVRAVFSNKADAFGLERARQAGIATHTLIASA
FDSREAYDRELIHEIDMYAPDVVVLAGFMRILSPAFVSHYAGRLLNIHPSLLPKYPGLHT
HRQALENGDEEHGTSVHFVTDELDGGPVILQAKVPVFAGDSEDDITARVQTQEHAIYPLV
ISWFADGRLKMHENAAWLDGQRLPPQGYAADE

# Drug_Target_2_Reaction:
10-formyltetrahydrofolate + N1-(5-phospho-D-ribosyl)glycinamide = tetrahydrofolate + N2-formyl-N1-(5-phospho-D-ribosyl)glycinamide

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
10-formyltetrahydrofolate + 1-N-(5-phospho-D- ribosyl)glycinamide = tetrahydrofolate + 2-N-formyl-1-N-(5- phospho-D-ribosyl)glycinamide

# Drug_Target_2_SwissProt_ID:
P08179

# Drug_Target_2_SwissProt_Name:
PUR3_ECOLI

# Drug_Target_2_Synonyms:
5'-phosphoribosylglycinamide transformylase
EC 2.1.2.2
GAR transformylase
GART

# Drug_Target_2_Theoretical_pI:
5.74

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Not Available

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
GART

# Drug_Target_3_GenBank_ID_Gene:
X54199

# Drug_Target_3_GenBank_ID_Protein:
31642

# Drug_Target_3_GeneCard_ID:
GART

# Drug_Target_3_Gene_Name:
GART

# Drug_Target_3_Gene_Sequence:
>3033 bp
ATGGCAGCCCGAGTACTTATAATTGGCAGTGGAGGAAGGGAACATACGCTGGCCTGGAAA
CTTGCACAGTCTCATCATGTCAAACAAGTGTTGGTTGCCCCAGGAAACGCAGGCACTGCC
TGCTCTGAAAAGATTTCAAATACCGCCATCTCAATCAGTGACCACACTGCCCTTGCTCAA
TTCTGCAAAGAGAAGAAAATTGAATTTGTAGTTGTTGGACCAGAAGCACCTCTGGCTGCT
GGGATTGTTGGGAACCTGAGGTCTGCAGGAGTGCAATGCTTTGGCCCAACAGCAGAAGCG
GCTCAGTTAGAGTCCAGCAAAAGGTTTGCCAAAGAGTTTATGGACAGACATGGAATCCCA
ACCGCACAATGGAAGGCTTTCACCAAACCTGAAGAAGCCTGCAGCTTCATTTTGAGTGCA
GACTTCCCTGCTTTGGTTGTGAAGGCCAGTGGTCTTGCAGCTGGAAAAGGGGTGATTGTT
GCAAAGAGCAAAGAAGAGGCCTGCAAAGCTGTACAAGAGATCATGCAGGAGAAAGCCTTT
GGGGCAGCTGGAGAAACAATTGTCATTGAAGAACTTCTTGACGGAGAAGAGGTGTCGTGT
CTGTGTTTCACTGATGGCAAGACTGTGGCCCCCATGCCCCCAGCACAGGACCATAAGCGA
TTACTGGAGGGAGATGGTGGCCCTAACACAGGGGGAATGGGAGCCTATTGTCCAGCCCCT
CAGGTTTCTAATGATCTATTACTAAAAATTAAAGATACTGTTCTTCAGAGGACAGTGGAT
GGCATGCAGCAAGAGGGTACTCCATATACAGGTATTCTCTATGCTGGAATAATGCTGACC
AAGAATGGCCCAAAAGTTCTAGAGTTTAATTGCCGTTTTGGTGATCCAGAGTGCCAAGTA
ATCCTCCCACTTCTTAAAAGTGATCTTTATGAAGTGATTCAGTCCACCTTAGATGGACTG
CTCTGCACATCTCTGCCTGTTTGGCTAGAAAACCACACCGCCCTAACTGTTGTCATGGCA
AGTAAAGGTTATCCTGGAGACTACACCAAGGGTGTAGAGATAACAGGGTTTCCTGAGGCT
CAAGCTCTAGGACTGGAGGTGTTCCATGCAGGCACTGCCCTCAAAAATGGCAAAGTAGTA
ACTCATGGGGGTAGAGTTCTTGCAGTCACAGCCATCCGGGAAAATCTCATATCAGCCCTT
GAGGAAGCCAAGAAAGGACTAGCTGCTATAAAGTTTGAGGGAGCAATTTATAGGAAAGAC
GTCGGCTTTCGTGCCATAGCTTTCCTCCAGCAGCCCAGGAGTTTGACTTACAAGGAATCT
GGAGTAGATATCGCAGCTGGAAATATGCTGGTCAAGAAAATTCAGCCTTTAGCAAAAGCC
ACTTCCAGATCAGGCTGTAAAGTTGATCTTGGAGGTTTTGCTGGTCTTTTTGATTTAAAA
GCAGCTGGTTTCAAAGATCCCCTTCTGGCCTCTGGAACAGATGGCGTTGGAACTAAACTA
AAGATTGCCCAGCTATGCAATAAACATGATACCATTGGTCAAGATTTGGTAGCAATGTGT
GTTAATGATATTCTGGCACAAGGAGCAGAGCCCCTCTTCTTCCTTGATTACTTTTCCTGT
GGAAAACTTGACCTCAGTGTAACTGAAGCTGTTGTTGCTGGAATTGCTAAAGCTTGTGGA
AAAGCTGGATGTGCTCTCCTTGGAGGTGAAACAGCAGAAATGCCTGACATGTATCCCCCT
GGAGAGTATGACCTAGCTGGGTTTGCCGTTGGTGCCATGGAGCGAGATCAGAAACTCCCT
CACCTGGAAAGAATCACTGAGGGTGATGTTGTTGTTGGAATAGCTTCATCTGGTCTTCAT
AGCAATGGATTTAGCCTTGTGAGGAAAATCGTTGCAAAATCTTCCCTCCAGTACTCCTCT
CCAGCACCTGATGGTTGTGGTGACCAGACTTTAGGGGACTTACTTCTCACGCCTACCAGA
ATCTACAGCCATTCACTGTTACCTGTCCTACGTTCAGGACATGTCAAAGCCTTTGCCCAT
ATTACTGGTGGAGGATTACTAGAGAACATCCCCAGAGTCCTCCCTGAGAAACTTGGGGTA
GATTTAGATGCCCAGACCTGGAGGATCCCCAGGGTTTTCTCATGGTTGCAGCAGGAAGGA
CACCTCTCTGAGGAAGAGATGGCCAGAACATTTAACTGTGGGGTTGGCGCTGTCCTTGTG
GTATCAAAGGAGCAGACAGAGCAGATTCTGAGGGATATCCAGCAGCACAAGGAAGAAGCC
TGGGTGATTGGCAGTGTGGTTGCACGAGCTGAAGGTTCCCCACGTGTGAAAGTCAAGAAT
CTGATTGAAAGCATGCAAATAAATGGGTCAGTGTTGAAGAATGGCTCCCTGACAAATCAT
TTCTCTTTTGAAAAAAAAAAGGCCAGAGTGGCTGTCTTAATATCTGGAACAGGATCGAAC
CTGCAAGCACTTATAGACAGTACTCGGGAACCAAATAGCTCTGCACAAATTGATATTGTT
ATCTCCAACAAAGCCGCAGTAGCTGGGTTAGATAAAGCGGAAAGAGCTGGTATTCCCACT
AGAGTAATTAATCATAAACTGTATAAAAATCGTGTAGAATTTGACAGTGCAATTGACCTA
GTCCTTGAAGAGTTCTCCATAGACATAGTCTGTCTTGCAGGATTCATGAGAATTCTTTCT
GGCCCCTTTGTCCAAAAGTGGAATGGAAAAATGCTCAATATCCACCCATCCTTGCTCCCT
TCTTTTAAGGGTTCAAATGCCCATGAGCAAGCCCTGGAAACCGGAGTCACAGTTACTGGG
TGCACTGTACACTTTGTAGCTGAAGATGTGGATGCTGGACAGATTATTTTGCAAGAAGCT
GTTCCCGTGAAGAGGGGTGATACTGTCGCAACTCTTTCTGAAAGAGTAAAATTAGCAGAA
CATAAAATATTTCCTGCAGCCCTTCAGCTGGTGGCCAGTGGAACTGTACAGCTTGGAGAA
AATGGCAAGATCTGTTGGGTTAAAGAGGAATGA

# Drug_Target_3_General_Function:
Nucleotide transport and metabolism

# Drug_Target_3_General_References:
2147474	Aimi J, Qiu H, Williams J, Zalkin H, Dixon JE: De novo purine nucleotide biosynthesis: cloning of human and avian cDNAs encoding the trifunctional glycinamide ribonucleotide synthetase-aminoimidazole ribonucleotide synthetase-glycinamide ribonucleotide transformylase by functional complementation in E. coli. Nucleic Acids Res. 1990 Nov 25;18(22):6665-72.
2183217	Schild D, Brake AJ, Kiefer MC, Young D, Barr PJ: Cloning of three human multifunctional de novo purine biosynthetic genes by functional complementation of yeast mutations. Proc Natl Acad Sci U S A. 1990 Apr;87(8):2916-20.
9224613	Kan JL, Moran RG: Intronic polyadenylation in the human glycinamide ribonucleotide formyltransferase gene. Nucleic Acids Res. 1997 Aug 1;25(15):3118-23.

# Drug_Target_3_HGNC_ID:
HGNC:4163

# Drug_Target_3_HPRD_ID:
00716

# Drug_Target_3_ID:
1043

# Drug_Target_3_Locus:
Not Available

# Drug_Target_3_Molecular_Weight:
107768

# Drug_Target_3_Name:
Trifunctional purine biosynthetic protein adenosine-3 [Includes: Phosphoribosylamine--glycine ligase

# Drug_Target_3_Number_of_Residues:
1010

# Drug_Target_3_PDB_ID:
Not Available

# Drug_Target_3_Pathway:
Azathioprine Pathway	SMP00427
Mercaptopurine Pathway	SMP00428
Methotrexate Pathway	SMP00432
Thioguanine Pathway	SMP00430

# Drug_Target_3_Pfam_Domain_Function:
PF00551	Formyl_trans_N
PF00586	AIRS
PF01071	GARS_A
PF02769	AIRS_C
PF02843	GARS_C
PF02844	GARS_N

# Drug_Target_3_Protein_Sequence:
>Trifunctional purine biosynthetic protein adenosine-3 [Includes: Phosphoribosylamine--glycine ligase
MAARVLIIGSGGREHTLAWKLAQSHHVKQVLVAPGNAGTACSEKISNTAISISDHTALAQ
FCKEKKIEFVVVGPEAPLAAGIVGNLRSAGVQCFGPTAEAAQLESSKRFAKEFMDRHGIP
TAQWKAFTKPEEACSFILSADFPALVVKASGLAAGKGVIVAKSKEEACKAVQEIMQEKAF
GAAGETIVIEELLDGEEVSCLCFTDGKTVAPMPPAQDHKRLLEGDGGPNTGGMGAYCPAP
QVSNDLLLKIKDTVLQRTVDGMQQEGTPYTGILYAGIMLTKNGPKVLEFNCRFGDPECQV
ILPLLKSDLYEVIQSTLDGLLCTSLPVWLENHTALTVVMASKGYPGDYTKGVEITGFPEA
QALGLEVFHAGTALKNGKVVTHGGRVLAVTAIRENLISALEEAKKGLAAIKFEGAIYRKD
VGFRAIAFLQQPRSLTYKESGVDIAAGNMLVKKIQPLAKATSRSGCKVDLGGFAGLFDLK
AAGFKDPLLASGTDGVGTKLKIAQLCNKHDTIGQDLVAMCVNDILAQGAEPLFFLDYFSC
GKLDLSVTEAVVAGIAKACGKAGCALLGGETAEMPDMYPPGEYDLAGFAVGAMERDQKLP
HLERITEGDVVVGIASSGLHSNGFSLVRKIVAKSSLQYSSPAPDGCGDQTLGDLLLTPTR
IYSHSLLPVLRSGHVKAFAHITGGGLLENIPRVLPEKLGVDLDAQTWRIPRVFSWLQQEG
HLSEEEMARTFNCGVGAVLVVSKEQTEQILRDIQQHKEEAWVIGSVVARAEGSPRVKVKN
LIESMQINGSVLKNGSLTNHFSFEKKKARVAVLISGTGSNLQALIDSTREPNSSAQIDIV
ISNKAAVAGLDKAERAGIPTRVINHKLYKNRVEFDSAIDLVLEEFSIDIVCLAGFMRILS
GPFVQKWNGKMLNIHPSLLPSFKGSNAHEQALETGVTVTGCTVHFVAEDVDAGQIILQEA
VPVKRGDTVATLSERVKLAEHKIFPAALQLVASGTVQLGENGKICWVKEE

# Drug_Target_3_Reaction:
10-formyltetrahydrofolate + N1-(5-phospho-D-ribosyl)glycinamide = tetrahydrofolate + N2-formyl-N1-(5-phospho-D-ribosyl)glycinamide

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
ATP + 5-phospho-D-ribosylamine + glycine = ADP + phosphate + 1-N-(5-phospho-D-ribosyl)glycinamide

# Drug_Target_3_SwissProt_ID:
P22102

# Drug_Target_3_SwissProt_Name:
PUR2_HUMAN

# Drug_Target_3_Synonyms:
AIR synthase
AIRS
EC 2.1.2.2
EC 6.3.3.1
EC 6.3.4.13
GAR transformylase
GARS
GART
Glycinamide ribonucleotide synthetase
Phosphoribosyl-aminoimidazole synthetase
Phosphoribosylformylglycinamidine cyclo-ligase
Phosphoribosylglycinamide formyltransferase
Phosphoribosylglycinamide synthetase

# Drug_Target_3_Theoretical_pI:
6.68

# Drug_Target_3_Transmembrane_Regions:
None

#END_DRUGCARD DB02236
